SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics announced the initiation of a randomized Phase 2…

MiNK Therapeutics · PRESS-RELEASE filed May 14, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 14, 2026 at 07:30 ET

MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT cell therapy agenT-797 in patients with acute lung injury and hypoxemic respiratory failure. The study, conducted in partnership with First Lviv Medical Union and UNBROKEN Ukraine, targets a large unmet need with no approved therapies, and preliminary data are expected in H2 2026. For a $55M market cap clinical-stage biotech, this represents a significant pipeline catalyst with potential to unlock a new indication beyond oncology.

  • Randomized Phase 2 trial (C-1300-02) initiated for agenT-797 in acute lung injury (ALI) with hypoxemic respiratory failure.
  • Study is placebo-controlled, evaluating survival, ventilator-free days, and secondary infections; preliminary data expected H2 2026.
  • AgenT-797 is an off-the-shelf allogeneic iNKT cell therapy, enabling rapid deployment in critical care without patient-specific manufacturing.
  • Prior Phase 1/2 data (Hammond et al., Nat Comms) showed improved survival and reduced secondary infections in virally induced ARDS.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access